Insider Trading in US Stocks | MiMedx Group disclosed two insider trading transactions and related details on March 17

K-LinePoet · 2026-04-02T04:36:06+00:00

On March 17, 2026, MiMedx Group disclosed stock sale transactions by executives Hulse William Frank IV and Maersk-Moller Kimberly, which took place on March 13, involving amounts of $88,700 and $29,600 respectively. At the same time, Hulse also made a large purchase on March 10. The company specializes in placental biologics, providing innovative solutions for healthcare.

K-LinePoet

2026-04-02 04:36:06

Abstract generation in progress

March 17, 2026, MiMedx Group (MDXG) disclosed two transactions involving company insiders.

On March 13, 2026, executive Hulse William Frank IV sold 20,200 shares.

[Recent Insider Transactions]

Disclosure date	Position	Name	Transaction date	Buy/Sell	Quantity	Price per share/US$	Total amount/US$
March 17, 2026	Executive	Maersk-Moller Kimberly	March 13, 2026	Sell	6762	4.38	29.6k
March 17, 2026	Executive	Hulse William Frank IV	March 13, 2026	Sell	20,200	4.38	88.7k
March 12, 2026	Executive	Hulse William Frank IV	March 10, 2026	Buy	74,900	4.50	337.1k
March 12, 2026	Executive	DOUG RICE	March 10, 2026	Buy	146,600	4.50	659.9k
March 12, 2026	Executive	Maersk-Moller Kimberly	March 10, 2026	Buy	21,600	4.50	97.1k
February 18, 2026	Executive	Whitlow Ricci S	February 13, 2026	Sell	62,000	5.12	317.2k
November 10, 2025	Executive	Maersk-Moller Kimberly	November 6, 2025	Sell	58,300	7.42	432.3k
July 7, 2025	Executive	DOUG RICE	July 3, 2025	Sell	12,700	6.34	80.8k
June 26, 2025	Executive	Maersk-Moller Kimberly	June 24, 2025	Sell	12,000	5.96	71.7k
June 23, 2025	Director	BEHRENS M KATHLEEN、BIERMAN JAMES L、HAWKINS WILLIAM A、LAURENCIN CATO T、Olson Tiffany、PUHY DOROTHY E	June 18, 2025	Buy	171,700	6.47	1.1106M

[Company Profile]

MiMedx Group, Inc. was incorporated in the state of Florida. The company is a pioneer and leader focused on helping humans heal with placental biologic products. With more than a decade of helping clinicians manage chronic and hard-to-heal wounds, MIMEDX is committed to providing a leading product portfolio for wound care, burn care, and surgical applications in the healthcare field. The company’s vision is to become a global leading provider of restorative solutions through relentless innovation, to restore quality of life. With deep expertise, leading peer-reviewed data, and an extensive library of additional scientific and real-world evidence in the placental biologics field, MIMEDX develops and distributes placental tissue allografts, which are manufactured using patented proprietary manufacturing processes and are suitable for multiple departments within healthcare.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.